Alkem Laboratories: Nomura raises target to ₹6,300

Market view: bearish tone despite selective positives

Alkem Laboratories has been in focus as brokerages balance improving growth guidance against near-term risks flagged in recent commentary. The stated market bias in the current setup is bearish, citing a sharp 23.8% drop in net profit even as revenue rose 14.6%, a combination seen as a sign of operational inefficiency. Regulatory overhang has also been highlighted after seven USFDA observations at the company’s Daman facility, adding another variable for investors tracking execution risk. At a portfolio level, the stance in the note is to stay overweight on healthcare services while remaining underweight on generic pharmaceuticals and active pharmaceutical ingredients (API). For Alkem specifically, the most watched trigger mentioned is a semaglutide launch planned for March 2026.

Nomura reiterates Buy, lifts target on Q2FY26 growth

Nomura reiterated its Buy rating on Alkem Laboratories after the company reported strong Q2FY26 growth across operating segments. The brokerage set a target price of ₹6,860 per share in one of the cited notes, while another cited update mentions a raised target of ₹6,300. Nomura’s central argument is that Alkem remains confident about its domestic business outlook and expects to grow at least 100-150 basis points ahead of the broader Indian pharmaceuticals market. In ex-US international markets, management expects sales growth in the high teens for FY26. Nomura also pointed to a meaningful improvement in the US business, with management now expecting double-digit growth in FY26 versus earlier guidance of mid-single-digit expansion. It added that valuation appears reasonable in its view, supported by domestic performance, export momentum, and prospects at Enzene Biosciences.

India growth expectations versus what the Street anticipated

A separate market commentary captured the Street’s expectations more bluntly, noting that investors were looking for “double-digit growth” in the India business this time. That gap between expectation and what was delivered or guided has been positioned as one factor behind stock volatility. The same commentary linked the stock’s sharp downtick to the announcement of an acquisition in the medtech space. Taken together, the narrative around Alkem in the latest set of notes is less about a single quarter and more about whether management can deliver growth while absorbing higher spending and integration costs.

Medtech acquisition: 55% stake in OcuTek for €180 million

Alkem is set to acquire a majority stake in OcuTek Holding, described as a Swiss-headquartered global medtech firm. The deal involves a 55% stake for €180 million. The commentary describes OcuTek as expected to be the third-largest global player in minimally invasive cardiac implants. But it also stresses that the target is loss-making, which has been cited as a key reason investors turned cautious in the near term. The deal’s rationale, the pace of turnaround, and the timeline for profitability are not detailed in the provided text, so the immediate market focus remains on the drag from losses and the strategic fit.

OcuTek financial profile as cited

The notes provide specific figures for OcuTek’s recent performance in Indian rupee terms. For 2024, OcuTek reported revenue of ₹397.8 crore and a loss of ₹185.7 crore. For 2025, loss is expected at around ₹67.65 crore. These numbers explain why the acquisition has been framed as a sentiment overhang, especially in a market environment that is already sensitive to margin pressure and cash-flow visibility.

Semaglutide launch in March 2026: key trigger

Management commentary cited in the note flags GLP-1 semaglutide as a key near-term growth driver, with a launch planned for March 2026. In the context of shifting product cycles across the pharma sector, this timeline is likely to be tracked closely alongside any updates on execution readiness and competitive intensity. The same collection of notes also reflects sector preferences turning more selective, with an overweight bias to healthcare services but caution on generic pharmaceuticals and APIs. That backdrop matters because Alkem’s incremental growth drivers will be judged against both domestic market growth and the company’s ability to sustain margins while investing behind launches.

Conflicting brokerage calls: Buy versus Underperform/Sell

Brokerage opinions in the provided material vary widely. Nomura remains constructive, with multiple target prices cited across different updates, including ₹5,430, ₹6,300, and ₹6,860, while retaining a Buy stance in the cited notes. Jefferies, in contrast, maintained an Underperform rating and cut its target price to ₹4,460, citing margin concerns and noting the company’s Q4 performance missed estimates due to lower margins. Choice Broking maintained a Sell rating with a target of ₹4,100, pointing to expectations of high single-digit overall revenue growth and noting there were no major US drug launches scheduled for FY26E/FY27E. Choice also highlighted India growth slowing over the past two quarters and flagged muted volume growth of around 1% versus about 2% expected in referenced products.

Stock moves: sharp reactions around results and notes

Alkem’s share price has reacted sharply to results and brokerage updates in the cited snippets. One update notes the stock jumped over 4% and traded at ₹5,374 at 11:04 AM after Nomura reaffirmed a Buy rating with a ₹5,430 target following strong Q1 results. Another line notes the stock jumped over 6% after results for the quarter ended June 30, 2025, driven by robust domestic and international performance. In a separate instance, Alkem shares declined 5% to ₹5,025 in intraday trade on the BSE after reporting Q4FY25 net profit of ₹306 crore, up 4.2% from ₹294 crore a year earlier. These moves underline how the stock has been sensitive to the balance between growth delivery and margin or execution concerns.

Market impact: growth guidance versus risk stack

The market debate reflected in the provided text centres on whether improving growth guidance is enough to offset a growing risk stack. On the positive side, Nomura points to domestic outperformance of 100-150 basis points versus the Indian pharma market, high-teens growth expected in ex-US international markets, and improved expectations for the US business to double-digit growth in FY26. On the negative side, the bearish framing highlights the mismatch between profit and revenue growth (23.8% profit drop alongside 14.6% revenue growth) and the added regulatory uncertainty from seven USFDA observations at Daman. The acquisition of a loss-making medtech firm further raises questions about near-term earnings quality, even if the strategic intent is to build a presence in minimally invasive cardiac implants. With higher R&D spending also referenced, investors are likely to keep focus on how incremental growth translates into profitability.

Why this matters: execution, margins, and capital allocation

This set of developments matters because Alkem is being evaluated on multiple fronts at once. The domestic business remains the anchor in most brokerage frameworks, and even a modest slowdown can change the earnings trajectory when market growth itself is expected at 8-9% in the coming year in one cited view. At the same time, management’s improved US guidance changes the narrative from stabilisation to growth, but it comes with the need to sustain compliance and operational delivery. Capital allocation is another live issue, because the OcuTek transaction is meaningful and the target is currently loss-making based on the cited numbers. The difference between broker targets and ratings shows that the market is still divided on whether the current risk-reward is favourable.

Conclusion: watch semaglutide timeline and regulatory updates

Alkem remains a stock where the headline growth story is being weighed against regulatory and margin-related risks. Nomura’s reiterated Buy and higher target(s) lean on domestic resilience, improving exports, and Enzene prospects, while Jefferies and Choice remain cautious on margins and growth visibility. The next key watchpoints highlighted in the material are the semaglutide launch planned for March 2026 and any follow-through on the seven USFDA observations at the Daman facility. Updates on the integration and performance trajectory of OcuTek will also matter, given the loss profile cited for 2024 and expectations for 2025.